Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets
Dendritic cell-based immunotherapy employs the patients’ immune system to fight neoplastic lesions spread over the entire body. This makes it an important therapy option for patients suffering from metastatic melanoma, which is often resistant to chemotherapy. However, conventional cellular vaccinat...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00165/full |
id |
doaj-bad4a0da1e854840a698540e4439420d |
---|---|
record_format |
Article |
spelling |
doaj-bad4a0da1e854840a698540e4439420d2020-11-24T22:58:55ZengFrontiers Media S.A.Frontiers in Immunology1664-32242014-04-01510.3389/fimmu.2014.0016585668Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsetsFlorian eWimmers0Gerty eSchreibelt1Annette E. Sköld2Carl G. Figdor3I. Jolanda M. ede Vries4I. Jolanda M. ede Vries5Radboud Institute for Molecular Life Sciences, Radboud University Medical CenterRadboud Institute for Molecular Life Sciences, Radboud University Medical CenterRadboud Institute for Molecular Life Sciences, Radboud University Medical CenterRadboud Institute for Molecular Life Sciences, Radboud University Medical CenterRadboud Institute for Molecular Life Sciences, Radboud University Medical CenterRadboud University Medical CenterDendritic cell-based immunotherapy employs the patients’ immune system to fight neoplastic lesions spread over the entire body. This makes it an important therapy option for patients suffering from metastatic melanoma, which is often resistant to chemotherapy. However, conventional cellular vaccination approaches, based on monocyte-derived dendritic cells, only achieved modest response rates despite continued optimization of various vaccination parameters. In addition, the generation of monocyte-derived dendritic cells requires extensive ex vivo culture conceivably hampering the immunogenicity of the vaccine. Recent studies, thus, focused on vaccines that make use of primary dendritic cells. Though rare in the blood, these naturally circulating dendritic cells can be readily isolated and activated thereby circumventing lengthy ex vivo culture periods. The first clinical trials not only showed increased survival rates but also the induction of diversified anticancer immune responses. Upcoming treatment paradigms aim to include several primary dendritic cell subsets in a single vaccine as preclinical studies identified synergistic effects between various antigen-presenting cells.http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00165/fullImmunotherapyMelanomaplasmacytoid dendritic cellsMonocyte-derived dendritic cellsmyeloid dendritic cellsdendritic cell vaccination |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Florian eWimmers Gerty eSchreibelt Annette E. Sköld Carl G. Figdor I. Jolanda M. ede Vries I. Jolanda M. ede Vries |
spellingShingle |
Florian eWimmers Gerty eSchreibelt Annette E. Sköld Carl G. Figdor I. Jolanda M. ede Vries I. Jolanda M. ede Vries Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets Frontiers in Immunology Immunotherapy Melanoma plasmacytoid dendritic cells Monocyte-derived dendritic cells myeloid dendritic cells dendritic cell vaccination |
author_facet |
Florian eWimmers Gerty eSchreibelt Annette E. Sköld Carl G. Figdor I. Jolanda M. ede Vries I. Jolanda M. ede Vries |
author_sort |
Florian eWimmers |
title |
Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets |
title_short |
Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets |
title_full |
Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets |
title_fullStr |
Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets |
title_full_unstemmed |
Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets |
title_sort |
paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived dcs to naturally circulating dc subsets |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2014-04-01 |
description |
Dendritic cell-based immunotherapy employs the patients’ immune system to fight neoplastic lesions spread over the entire body. This makes it an important therapy option for patients suffering from metastatic melanoma, which is often resistant to chemotherapy. However, conventional cellular vaccination approaches, based on monocyte-derived dendritic cells, only achieved modest response rates despite continued optimization of various vaccination parameters. In addition, the generation of monocyte-derived dendritic cells requires extensive ex vivo culture conceivably hampering the immunogenicity of the vaccine. Recent studies, thus, focused on vaccines that make use of primary dendritic cells. Though rare in the blood, these naturally circulating dendritic cells can be readily isolated and activated thereby circumventing lengthy ex vivo culture periods. The first clinical trials not only showed increased survival rates but also the induction of diversified anticancer immune responses. Upcoming treatment paradigms aim to include several primary dendritic cell subsets in a single vaccine as preclinical studies identified synergistic effects between various antigen-presenting cells. |
topic |
Immunotherapy Melanoma plasmacytoid dendritic cells Monocyte-derived dendritic cells myeloid dendritic cells dendritic cell vaccination |
url |
http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00165/full |
work_keys_str_mv |
AT florianewimmers paradigmshiftindendriticcellbasedimmunotherapyfrominvitrogeneratedmonocytederiveddcstonaturallycirculatingdcsubsets AT gertyeschreibelt paradigmshiftindendriticcellbasedimmunotherapyfrominvitrogeneratedmonocytederiveddcstonaturallycirculatingdcsubsets AT annetteeskold paradigmshiftindendriticcellbasedimmunotherapyfrominvitrogeneratedmonocytederiveddcstonaturallycirculatingdcsubsets AT carlgfigdor paradigmshiftindendriticcellbasedimmunotherapyfrominvitrogeneratedmonocytederiveddcstonaturallycirculatingdcsubsets AT ijolandamedevries paradigmshiftindendriticcellbasedimmunotherapyfrominvitrogeneratedmonocytederiveddcstonaturallycirculatingdcsubsets AT ijolandamedevries paradigmshiftindendriticcellbasedimmunotherapyfrominvitrogeneratedmonocytederiveddcstonaturallycirculatingdcsubsets |
_version_ |
1725646040401444864 |